0
Abstract: Poster Presentations |

5-YEAR SURVIVAL RATE OF LUNG CANCER PATIENTS IN AN INNER CITY HOSPITAL FREE TO VIEW

Feroz F. Noori, MD*; Asha Karippot, MD; Besher Kabak, MD; Robby Ayoub, MD; Daniel Suffin, DO; Riar Sandeep, MD; Justin Pi, MD; Gunwant Guron, MD; Alan Klukowicz, MD; Richard A. Miller, MD
Author and Funding Information

Saint Michael Medical Center, Newark, NJ


Chest


Chest. 2009;136(4_MeetingAbstracts):21S. doi:10.1378/chest.136.4_MeetingAbstracts.21S-c
Text Size: A A A
Published online

Abstract

PURPOSE:  Lung cancer is the cause of 921,000 deaths each year worldwide, accounting for 17.8% of cancer-related deaths. The 5-year overall survival rate in United States and Europe are 14% and 8% respectively. For small cell lung cancer (SCLC), the 5-year survival rate is 1–5%.To demonstrate the 5 year survival rate in different types of lung cancer in various stages in an inner city hospital.

METHODS:  This retrospective cohort study was conducted of adult patients diagnosed with lung cancer using data from 2000–2004 in an inner city hospital cancer registry. Patient demographics like age and sex noted. Both small cell and non-small cell lung cancer patients included in the study. Survival rate at 5 years were reviewed.

RESULTS:  A total number of 174 patient charts reviewed. Mean age of patients was 64.5. 57.5% of patients are male and 42.5% female. Mean 5 year survival for non small cell lung cancer from stage 1 to 4 were 9%, 16%, 3.6% and 2.6 % respectively. None of the small cell cancer patients survived for 5 years.

CONCLUSION:  Our study shows no difference in overall survival rates among lung cancer patients from our inner city hospital population and national average.

CLINICAL IMPLICATIONS:  There was no difference in the survival rates among lung cancer patients from our inner city hospital compared with the national average, despite the differences in socioeconomic status and health care access. This suggests that lung cancer universally has a poor prognosis. This further highlights the importance of better screening and treatment modalities.

DISCLOSURE:  Feroz Noori, No Financial Disclosure Information; No Product/Research Disclosure Information

Tuesday, November 3, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543